China NMPA Inspection - Wuhan Chaohao Biotechnology Co., Ltd. - June 26, 2026

On June 26, 2026, the National Medical Products Administration (NMPA) issued Announcement No. 23 regarding unannounced inspections of Wuhan Chaohao Biotechnology Co., Ltd. and Guangxi Xiangzhou Yidan Biotechnology Co., Ltd. The inspections revealed that both companies had significant violations of the 'Cosmetics Supervision and Management Regulations' and the 'Cosmetics Production Quality Management Standards.' Specifically, their production quality management systems were found to have serious deficiencies that could compromise product safety. Under the national regulatory framework, the NMPA has mandated that the Hubei Provincial and Guangxi Zhuang Autonomous Region Drug Administrations oversee the necessary enforcement actions. Both companies have been ordered to immediately suspend all production and business operations. Furthermore, they are required to rectify all identified issues to bring their facilities into compliance with national standards. Local authorities have initiated formal investigations into the suspected illegal activities to ensure public safety and accountability within the cosmetics industry. These measures reflect a strict approach to maintaining quality control across the manufacturing sector.